Cargando…

Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model

PURPOSE: The purpose of these Phase III studies was to evaluate the efficacy and safety of cetirizine ophthalmic solution 0.24% compared with vehicle in the treatment of allergen-induced conjunctivitis using the Ora conjunctival allergen challenge (CAC)(®) model. METHODS: The single-center (Study 1)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meier, Edward J, Torkildsen, Gail L, Gomes, Paul J, Jasek, Mark C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296187/ https://www.ncbi.nlm.nih.gov/pubmed/30587908 http://dx.doi.org/10.2147/OPTH.S185835

Ejemplares similares

Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects
por: Malhotra, Ranjan P, et al.
Publicado: (2019)

Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model
por: Torkildsen, Gail, et al.
Publicado: (2015)

Birch allergen challenges in allergic conjunctivitis using standard conjunctival allergen challenge and environmental exposure chamber
por: Gherasim, Alina, et al.
Publicado: (2021)

Characterization of Conjunctival Sac Microbiome from Patients with Allergic Conjunctivitis
por: Song, Hang, et al.
Publicado: (2022)

Treatment of allergic conjunctivitis with bepotastine besilate ophthalmic solution 1.5%
por: Bergmann, Mark T, et al.
Publicado: (2014)

Allergic conjunctivitis and the most common allergens in Northern Greece
por: Almaliotis, Diamantis, et al.
Publicado: (2013)

Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis
por: McLaurin, Eugene, et al.
Publicado: (2017)

Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis
por: Cavet, Megan E, et al.
Publicado: (2018)

Topical cyclosporine versus allergen specific immunotherapy in perennial allergic conjunctivitis
por: Dogan, Ceylan Uslu, et al.
Publicado: (2022)

Conjunctival Sac Microbiome in Infectious Conjunctivitis
por: Mohamed, Yasser Helmy, et al.
Publicado: (2021)

Conjunctival macrophages act as antigen-presenting cells in the conjunctiva during the development of experimental allergic conjunctivitis
por: Ishida, Waka, et al.
Publicado: (2010)

Production profile of lipid mediators in conjunctival lavage fluid in allergic and infectious conjunctivitis in guinea pigs
por: Hayashi, Akane, et al.
Publicado: (2023)

Microbial Delivery Vehicles for Allergens and Allergen-Derived Peptides in Immunotherapy of Allergic Diseases
por: Zahirović, Abida, et al.
Publicado: (2018)

Tear levels of neuropeptides increase after specific allergen challenge in allergic conjunctivitis
por: Sacchetti, Marta, et al.
Publicado: (2011)

Clinical comparison of the efficacy of spirulina platensis and cetirizine for treatment of allergic rhinitis
por: Nourollahian, Morteza, et al.
Publicado: (2020)

Update and clinical utility of alcaftadine ophthalmic solution 0.25% in the treatment of allergic conjunctivitis
por: Chigbu, DeGaulle I, et al.
Publicado: (2015)

Reproxalap Improves Signs and Symptoms of Allergic Conjunctivitis in an Allergen Chamber: A Real-World Model of Allergen Exposure
por: Clark, David, et al.
Publicado: (2022)

Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis
por: Ono, Santa J, et al.
Publicado: (2011)

Conjunctivitis with Monkeypox Virus Positive Conjunctival Swabs
por: Meduri, Enrico, et al.
Publicado: (2022)

Allergic conjunctivitis
por: Rathi, Varsha M, et al.
Publicado: (2017)

Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects
por: Araie, Makoto, et al.
Publicado: (2015)

Cetirizine for the treatment of allergic diseases in children: A systematic review and meta-analysis
por: Zhou, Pengxiang, et al.
Publicado: (2022)

Azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitis
por: Williams, Patricia B, et al.
Publicado: (2010)

Conjunctival Intraepithelial Lymphocytes, Lacrimal Cytokines and Ocular Commensal Microbiota: Analysis of the Three Main Players in Allergic Conjunctivitis
por: Zarzuela, José Carlos, et al.
Publicado: (2022)

Allergic conjunctivitis in Asia
por: Thong, Bernard Yu-Hor
Publicado: (2017)

Multiple Allergen Simultaneous Test-Immunoblot Assay for Immunoglobulin E Detection in Patients with Isolated Allergic Conjunctivitis
por: Han, Jung Yeob, et al.
Publicado: (2021)

Pruritus after discontinuation of cetirizine
por: Chung, Amy H., et al.
Publicado: (2019)

364 Zero Itch in Eyes Treated With Olopatadine Hydrochloride Ophthalmic Solution, 0.2% in Bilateral Conjunctival Allergen Challenge Studies
por: Blaiss, Michael S., et al.
Publicado: (2012)

Pseudomembranous Conjunctivitis: A Possible Conjunctival Foreign Body Aetiology
por: Ho, Dawn, et al.
Publicado: (2020)

Conjunctival chronic lymphocytic leukemia presenting as bilateral chronic conjunctivitis
por: Hakim, Farida, et al.
Publicado: (2022)

Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
por: Hoy, Sheridan M.
Publicado: (2018)

Cetirizine modifies quality of life and symptoms in children with seasonal allergic rhinitis: a pilot study
por: Benazzo, Marco, et al.
Publicado: (2021)

Recognition of allergic conjunctivitis in patients with allergic rhinitis
por: Williams, Daniel C, et al.
Publicado: (2013)

Allergic conjunctivitis in Jos-Nigeria
por: Malu, Keziah N.
Publicado: (2014)

Current Knowledge in Allergic Conjunctivitis
por: Villegas, Beatriz Vidal, et al.
Publicado: (2021)

Therapeutic Targets in Allergic Conjunctivitis
por: Labib, Bisant A., et al.
Publicado: (2022)

Diagnostic approach and grading scheme for canine allergic conjunctivitis
por: Delgado, Esmeralda, et al.
Publicado: (2023)

Correction to: Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension
por: Hoy, Sheridan M.
Publicado: (2018)

Latanoprostene bunod ophthalmic solution 0.024% in the treatment of open-angle glaucoma: design, development, and place in therapy
por: Addis, Victoria M, et al.
Publicado: (2018)

Elevated levels of prostaglandin E(2) in the tears of patients with severe allergic conjunctivitis and primary cultured conjunctival cells are suppressed by ketotifen and dexamethasone
por: Yamanishi, Ryutaro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n97s984oc8c15ui6ufl2f1pi7b